ClinicalTrials.gg
CompletedNCT02135705LOWERUpdated May 12, 2026

LOWER: Lomitapide Observational Worldwide Evaluation Registry

An observational study in Homozygous Familial Hypercholesterolemia, sponsored by Amryt Pharma. Completed at 71 sites in 8 countries. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Amryt Pharma (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
260
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States — 7 open to participants now, 9 under way, 4 of them phase 3. Homozygous Familial Hypercholesterolemia · United States.

Started
2014
the only one that year
Observational
5 of 36
2 open now
Registered
13th of 36
by date
Lead sponsor
1 of 36
Amryt Pharma

Among the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, this one is the only one that started in 2014, is one of 5 observational ones, and was the 13th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

7 of the 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Homozygous Familial Hypercholesterolemia with a site in United States, or all of them as a file.
02

Study summary

This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.

Read the detailed description

To evaluate the occurrence of adverse events of special interest, long term effectiveness of lomitapide, and to evaluate whether prescribers of lomitapide are following screening and monitoring recommendations as specified in product labeling.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated with lomitapide who agree to participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of all ages, including minors, who have initiated commercial treatment with lomitapide prior to or at time of registry enrolment.
  • Patients who have the ability to understand the requirements of the study and provide written to comply with the study data collection procedures or paediatric patients with the consent of a parent or legal guardian.

Patients ≥7 years of age (or above the age determined by the IRB/EC and in accordance with the local regulations and requirements) must also provide written informed assent forms.

Exclusion criteria

Exclusion Criteria:

  • Patients who are receiving lomitapide in clinical trials or through compassionate use, where patients are followed under a separate protocol.
  • Patients receiving an agent, defined as any drug or biologic agent other than lomitapide that has not received market authorization in the country of participation, at time of lomitapide initiation and continuing to receive an investigational agent at time of registry enrolment. These patients may be enrolled if receiving lomitapide when the investigational agent is discontinued..
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
260 participants (actual)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Lomitapide

    Lomitapide as prescribed by Physician.

    Drug: Lomitapide

Interventions

06

What researchers measure

Primary outcomes

  1. Hepatic Abnormalities

    to evaluate the occurrence of hepatic abnormalities

    Time frame: patients will be followed for 10 years

Secondary outcomes

  1. Gastrointestinal (GI) Events

    to evaluate the occurrence of GI events

    Time frame: patients will be followed for 10 years

  2. Tumors

    to evaluate any occurrence of tumors (small bowel, hepatic, colorectal or pancreatic)

    Time frame: patients will be followed for 10 years

  3. Events associated with coagulopathy

    to evaluate the occurrence of events associated with coagulopathy (abnormal bleeding, cerebral haemorrhage or GI bleeding)

    Time frame: patients will be followed for 10 years

  4. Major Adverse Cardiovascular Events (MACE) events

    to evaluate the occurrence of MACE events

    Time frame: patients will be followed for 10 years

  5. Death, including cause of death

    to evaluate the occurrence and cause of death

    Time frame: patients will be followed for 10 years

  6. Pregnancy

    to evaluate the occurrence and outcomes of pregnancy in females of reproductive potential treated with lomitapide. Patients who become pregnant will be offered enrolment into a separate Pregnancy Exposure Registry (PER).

    Time frame: patients will be followed for 10 years

  7. Serum lipid levels

    to evaluate the long-term effectiveness of lomitapide in maintaining control of serum lipid levels in a clinical practice setting.

    Time frame: patients will be followed for 10 years

  8. Prescriber behavior

    to evaluate whether prescribers of lomitapide enrolled at registry sites are following the screening and monitoring recommendations as specified in the PI and the prescriber educational materials aimed at risk minimization.

    Time frame: patients will be followed for 10 years

07

Study locations

71 sites
  • Brookwood Baptist Medical Center
    Birmingham, Alabama 35209, United States
  • Springhill Physician Practices
    Mobile, Alabama 36608, United States
  • Northern Arizona Healthcare
    Cottonwood, Arizona 86326, United States
  • Scottsdale Family Health
    Phoenix, Arizona 85018, United States
  • Pima Heart
    Tucson, Arizona 85718, United States
  • Arkansas Heart Center
    Fort Smith, Arkansas 72901, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of Colorado Health
    Aurora, Colorado 80045, United States
  • Alfieri Cardiology
    Newark, Delaware 19713, United States
  • Preventative Cardiology, Inc.
    Boca Raton, Florida 33434, United States
  • Florida Lipid Institute
    Winter Park, Florida 32792-2223, United States
  • Piedmont Heart Institute
    Atlanta, Georgia 30309, United States
  • Atlanta Heart Specialists
    Cumming, Georgia 30041, United States
  • Northside Hospital, Inc.
    Cumming, Georgia 30041, United States
  • Comprehensive Cardiovascular Care
    Gurnee, Illinois 60031, United States
  • Community Health Network
    Indianapolis, Indiana 46250, United States
  • St. Vincent Medical Group, Inc.
    Indianapolis, Indiana 46290, United States
  • Henry County Medical Center
    New Castle, Kentucky 40050, United States
  • Cardiovascular Institute of the South
    Houma, Louisiana 70360, United States
  • Get Well Immediate Care
    Towson, Maryland 21204, United States
  • Complete Family Care Cholesterol Treatment Center
    Sterling Heights, Michigan 48314, United States
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
  • HealthEast Care System
    Saint Paul, Minnesota 55102, United States
  • Stern Cardiovascular Foundation
    Southaven, Mississippi 38671, United States
  • Methodist Physicians Clinic
    Omaha, Nebraska 68114, United States
  • 201 Route 17 North
    Rutherford, New Jersey 07070, United States
  • Valley Medical Group
    Wyckoff, New Jersey 07481, United States
  • Murray Hill Medical Group
    New York, New York 10016, United States
  • NY Heart Center
    Syracuse, New York 13210, United States
  • Pediatric Cardiology Associates
    Syracuse, New York 13210, United States
  • Cardiology Specialists of the Carolinas PA
    Charlotte, North Carolina 28204, United States
  • Cardiology Specialists Of Carolina
    Charlotte, North Carolina 28211, United States
  • The Heart Care Group, PC
    Allentown, Pennsylvania 18103, United States
  • St. Luke's University Health Network - Pennsylvania
    Bethlehem, Pennsylvania 18015, United States
  • Lehigh Valley Hospital And Health Network
    East Stroudsburg, Pennsylvania 18301, United States
  • Cardiology Consultants of Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • Thomas Jefferson University Health System
    Philadelphia, Pennsylvania 19148, United States
  • Palmetto Health
    Columbia, South Carolina 29203, United States
  • 317 Saint Francis Dr.
    Greenville, South Carolina 29601, United States
  • Cardiovascular Specialists of Texas
    Austin, Texas 78758, United States
  • Baylor Scott & White Health
    Dallas, Texas 75226, United States
  • The University of Vermont Health Network
    Burlington, Vermont 05401-1473, United States
  • West Virginia University Medicine
    Morgantown, West Virginia 26506, United States
  • Ascension
    Milwaukee, Wisconsin 53211, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Aspirus Research Institute
    Wausau, Wisconsin 54401, United States
  • Clinica de Salud de Chaco
    Reconquista, Chaco CPA H3500BJS, Argentina
  • Nova Scotia Health Authority
    Halifax, Nova Scotia B3H2Y9, Canada
  • Robarts Research Institute
    London, Ontario N6A5B7, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H7K9, Canada
  • McGill University
    Montreal, Quebec H4A3J1, Canada
  • Centre Hospitalier Régional Universitaire de Lille
    Lille, Cedex 59037, France
  • Centre Hospitalier Universitaire Lyon
    Bron, Lyon 69677, France
  • Centre Hospitalier Universitaire Strasbourg
    Strasbourg, 67000, France
  • Metropolitan Hospital
    Piraeus, Piraeus 18547, Greece
  • University General Hospital of Ioannina
    Ioannina, 45500, Greece
  • Azienda Ospedaliero Universi consorziale policlinico di Bari
    Bari, Bari 70120, Italy
  • Policlinico S. Orsola-Malpighi
    Bologna, BO 40138, Italy
  • Azienda Ospedaliera G. Brotzu
    Cagliari, CA 09134, Italy
  • ASST Grande Ospedale Metropolitano Niguarda
    Milan, MI 20162, Italy
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
    Palermo, PA 90127, Italy
  • Azienda Ospedaliera Universita di Padova
    Padova, PD 35128, Italy
  • CNR Regione Toscana - Fondazione Toscana Gabriele Monasterio
    Pisa, Pisa 56124, Italy
  • Università degli Studi di Roma La Sapienza
    Roma, RM 00161, Italy
  • Università degli Studi di Roma La Sapienza
    Roma, Rome 00161, Italy
  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga
    Orbassano, TO 10043, Italy
  • Azienda Ospedaliera Specialistica Dei Colli
    Naples, 80131, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Naples, 80131, Italy
  • Radboud Universiteit Medisch Centrum
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, South Holland 3015 GD, Netherlands
  • Imperial College Healthcare - NHS Trust
    London, London W12 0NN, United Kingdom
08

References and documents

Publications

  • Larrey D, D'Erasmo L, O'Brien S, Arca M; Italian Working Group on Lomitapide. Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia. Liver Int. 2023 Feb;43(2):413-423. doi: 10.1111/liv.15497. Epub 2022 Dec 30. PubMed 36520008 ↗
  • Giammanco A, Cefalu AB, Noto D, Averna MR. Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. Curr Med Chem. 2020;27(23):3773-3783. doi: 10.2174/0929867326666190121120735. PubMed 30663562 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Apr 2026, 145 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2014
First posted
May 12, 2014
StartActual
Mar 18, 2014
Primary completionActual
Apr 27, 2026
CompletionActual
Apr 27, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02135705
Lead sponsor
Amryt Pharma
Responsible party
Sponsor
First posted
May 12, 2014
Start date
Mar 18, 2014
Primary completion
Apr 27, 2026
Completion
Apr 27, 2026
Last update
May 12, 2026

Study contacts

Janet Boylan
study director · Amryt Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion